Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: Six-Year Results of Primary Selective Laser Trabeculoplasty versus Eye Drops for the Treatment of Glaucoma and Ocular Hypertension

AI Generated Summary*

UK randomized trial extension comparing initial selective laser trabeculoplasty (SLT) with IOP-lowering drops in untreated open-angle glaucoma or ocular hypertension. Of 692 patients finishing year 3, 633 entered the extension (313 SLT, 320 drops), and 524 completed 72 months. Quality of life on EQ-5D, GUI and GQL-15 did not differ. The Glaucoma Symptom Scale was higher with SLT (83.6 vs 81.3) at 72 months only, judged unlikely to matter clinically. Drop-free control without incisional surgery applied to 69.8% of SLT eyes versus 18.0% of drops eyes. Progression affected 19.6% of SLT eyes versus 26.8% of drops eyes, and SLT eyes needed fewer trabeculectomies (13 vs 32) and cataract operations (57 vs 95). Laser treatment caused no serious adverse events.

*This summary was generated by AI and is published unedited. Oku does not alter these summaries. It may contain errors or omissions and is provided for general informational purposes only. Oku does not guarantee its accuracy, completeness, or reliability. For authoritative information, please refer to the original, peer-reviewed article.